Mechanisms of effects of complement inhibition in murine collagen-induced arthritis

Arthritis and Rheumatism

Volumn 46, Issue 11, 2002, Pages 3065-3075

  Banda, Nirmal K ^a   Kraus, Damian ^a   Vondracek, Andrea ^a   Huynh, Long H ^a   Bendele, Alison ^b   Holers, V Michael ^a   Arend, William P ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b BolderPATH   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COLLAGEN TYPE 2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY DETECTION; ARTHRITIS; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; COLLAGEN; COMPLEMENT ACTIVATION; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C5; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MICE; MICE, INBRED DBA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036847172     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10591     Document Type: Article

References (40)

1. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001;103:407-16.
2. Yang HT, Jirholt J, Svensson L, Sundvall M, Jansson L, Petersson U, et al. Identification of genes controlling collagen-induced arthritis in mice: Striking homology with susceptibility loci previously identified in the rat. J Immunol 1999;163:2916-21.
3. Trentham DE, Townes AS, Kang AH. Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J Clin Invest 1978;61:89-96.
4. Morgan K, Clague RB, Shaw MJ, Firth SA, Twose TM, Holt PJL. Native type II collagen-induced arthritis in the rat: The effect of complement depletion by cobra venom factor. Arthritis Rheum 1981;24:1356-62.
5. Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice. J Exp Med 1983;158:378-92.
6. Kerwar SS, Englert ME, McReynolds RA, Landes MJ, Lloyd JM, Oronsky AL, et al. Type II collagen-induced arthritis: Studies with purified anticollagen immunoglobulin. Arthritis Rheum 1983;26:1120-31.
7. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Soluble complement receptor 1 (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin Exp Immunol 2000;119:210-6.
8. Dreja H, Annenkov A, Chernajovsky Y. Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis Rheum 2000;43:1698-709.
9. Watson WC, Townes AS. Genetic susceptibility to murine collagen-induced arthritis: Proposed relationship to the IgG2 autoantibody subclass response, complement C3, major histocompatibility complex (MHC) and non-MHC loci. J Exp Med 1985;162:1878-91.
10. Watson WC, Brown PS, Pitcock JA, Townes AS. Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57B1/6 normal and beige (Chediak- Higashi) strains: Evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum 1987;30:460-5.
11. Banerjee S, Anderson GD, Luthra HS, David CS. Influence of complement C5 and Vβ T cell mutations on susceptibility to collagen-induced arthritis in mice. J Immunol 1989;142:2237-43.
12. Reife RA, Loutis N, Watson WC, Hasty KA, Stuart JM. SWR mice are resistant to collagen-induced arthritis but produce potentially arithtogenic antibodies. Arthritis Rheum 1991;34:776-81.
13. Spinella DG, Jeffers JR, Reife RA, Stuart JM. The role of C5 and T-cell receptor Vβ genes in susceptibility to collagen-induced arthritis. Immunogenetics 1991;34:23-7.
14. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 1995;92:8955-9.
15. Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, Matis LA. A role for complement in antibody-mediated inflammation: C5-deficient mice are resistant to collagen-induced arthritis. J Immunol 2000;164:4340-7.
16. Mussener A, Litton MJ, Lindros E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997;107:485-93.
17. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Clin Exp Immunol 1997;107:507-12.
18. Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 1999;42:1109-18.
19. Gabay C, Marinova-Mutafchieva L, Williams RO, Gigley JP, Butler DM, Feldmann M, et al. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: A possible role in the resolution of arthritis. Arthritis Rheum 2001;44:451-62.
20. Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 1992;175:121-9.
21. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998;160:4553-60.
22. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Krause D, et al. Transgenic mice overexpressing the complement inhibitor Crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med 1998;188:1321-31.
23. Kleinau S, Martinsson P, Heyman B. Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors. J Exp Med 2000;191:1611-6.
24. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000;43:2648-59.
25. Van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001;3:18-26.
26. Bandt MD, Grossin M, Driss F, Pincemail J, Babin-Chevaye C, Pasquier C. Vitamin E uncouples joint destruction and clinical inflammation in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2002;46:522-32.
27. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:1-11.
28. Rehrig S, Fleming SD, Anderson J, Guthridge JM, Rakstang J, McQueen CE, et al. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol 2001;167:5921-7.
29. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002;168:3601-7.
30. Hietala MA, Jonsson I-M, Tarkowski A, Kleinau S, Pekna M. Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol 2002;169:454-9.
31. Zwirner J, Fayyazi A, Götze O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999;36:877-84.
32. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999;162:4018-23.
33. Yang D, Chen Q, Stoll S, Chen X, Howard OMZ, Oppenheim JJ. Differential regulation of responsiveness to fMLP and C5a upon dendritic cell maturation: Correlation with receptor expression. J Immunol 2000;165:2694-702.
34. Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: Role of C5a in the acute inflammatory phase. Ann Rheum Dis 1990;49:747-52.
35. Heller T, Hennecke M, Baumann U, Gessner JE, Meyer zu Vilsendorf A, Maensch M, et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol 1999;163:985-94.
36. Schindler R, Gelfand JA, Dinarello CA. Recombinant C5 stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: Translational signal provided by lipopolysaccharide or IL-1 itself. Blood 1990;76:1631-8.
37. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, et al. A new biologic role for C3a and C3a desArg: Regulation of TNF-α and IL-1β synthesis. J Immunol 1996;156:3455-60.
38. Linton SM, Williams AS, Dodd I, Smith R, Williams BD, Morgan BP. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 2000;43:2590-7.
39. Smith GP, Smith RAG. Membrane-targeted complement inhibitors. Mol Immunol 2001;38:249-55.
40. Mizuno M, Nishikawa K, Spiller OB, Morgan BP, Okada N, Okada H, et al. Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis Rheum 2001;44:2425-34.